MMNFF · Medmen Enterprises, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $158.60M | $155.29M |
| Cost of Revenue | $71.08M | $99.94M |
| Gross Profit | $69.73M | $55.35M |
| R&D | - | - |
| SG&A | $108.72M | $192.74M |
| Total Operating Expenses | $238.66M | $487.62M |
| D&A | $25.65M | $40.51M |
| Operating Income | ($168.93M) | ($432.27M) |
| Interest Expense | - | - |
| Income Tax | ($9.90M) | ($40.93M) |
| Net Income | $210.89M | $526.53M |
| EPS - Basic | - | - |
| EPS - Diluted | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $10.80M | $32.25M |
| Accounts Receivable | - | - |
| Inventory | $10.01M | $20.09M |
| Accounts Payable | - | - |
| Current Assets | $161.50M | $96.68M |
| Total Assets | $323.22M | $472.46M |
| Current Liabilities | $326.42M | $288.61M |
| Long-term Debt | - | - |
| Total Liabilities | $641.74M | $726.10M |
| Stockholders' Equity | $151.81M | $191.76M |
| Retained Earnings | ($905.42M) | ($717.23M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($62.53M) | ($109.70M) |
| Investing Cash Flow | ($10.87M) | ($19.34M) |
| Financing Cash Flow | $72.90M | $107.13M |
| CapEx | $9.04M | $57.45M |
| Free Cash Flow | ($71.57M) | ($167.15M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | 44.0% | 35.6% |
| Operating margin | -106.5% | -278.4% |
| EBITDA margin | -90.3% | -252.3% |
| Net margin | 133.0% | 339.1% |
| Free cash flow margin | -45.1% | -107.6% |
| FCF / Net income | -0.34 | -0.32 |
| R&D / Revenue | - | - |
| SG&A / Revenue | 68.6% | 124.1% |
| Effective tax rate | -4.9% | -8.4% |
| Return on assets | 65.2% | 111.4% |
| Return on equity | 138.9% | 274.6% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 0.49 | 0.33 |
| Quick ratio | 0.46 | 0.27 |
| Cash ratio | 0.03 | 0.11 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 2.13 | 2.46 |
| Liabilities / Assets | 1.99 | 1.54 |
| Efficiency | ||
| Asset turnover | 0.49 | 0.33 |
| Inventory turnover | 7.10 | 4.97 |
| Days sales outstanding | - | - |
| Days inventory outstanding | 51d | 73d |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 2.1% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | 26.0% | - |
| Operating income growth (YoY) | 60.9% | - |
| Net income growth (YoY) | -59.9% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | 57.2% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -20.8% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-3.77
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Retail-Retail Stores, NEC
Comparing MedMen Enterprises against the 5 most active filers in the same SIC group.